<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39427003</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023.</ArticleTitle><Pagination><StartPage>24561</StartPage><MedlinePgn>24561</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24561</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-74729-2</ELocationID><Abstract><AbstractText>Research on Guillain-Barré syndrome (GBS) as a neurological adverse effect of vaccines on a global scale is scarce, highlighting the need for further investigation to evaluate its long-term impact and associated risk factors comprehensively. Hence, this study aims to assess the global burden of vaccine-associated GBS and its associated vaccines. This study utilized data from VigiBase, the World Health Organization global database of adverse event reports of medicines and vaccines, encompassing the period from 1967 to 2023 (total reports, n = 131,255,418) to investigate vaccine-associated GBS. Reported odds ratios (ROR) and information components (IC) were analyzed to assess the association between 19 vaccines and the occurrence of vaccine-associated GBS over 170 countries. We identified 15,377 (8072 males [52.49%]) reports of vaccine-associated GBS among 22,616 reports of all drugs-cause GBS from 1978 to 2023. Cumulative reports of vaccine-associated GBS have been increasing steadily over time, with a notable surge observed since the commencement of COVID-19 vaccines administration in 2020. Most vaccines showed significant associations with GBS such as Ad5-vectored COVID-19 vaccines (ROR, 14.88; IC, 3.66), COVID-19 mRNA vaccines (ROR, 9.66; IC, 2.84), and inactivated whole-virus COVID-19 vaccines (ROR, 3,29; IC 1.69). Influenza vaccines showed the highest association (ROR, 77.91; IC 5.98). Regarding age-and sex-specific risks, the association remained similar regardless of sex, with an increased association observed with advancing age. The mean time to onset was 5.5 days. Amid the COVID-19 pandemic, the reports of GBS surged in response to widespread COVID-19 vaccination. Nonetheless, COVID-19 vaccines exhibited the lowest association compared to other vaccines. Vigilance for at least one-week post-vaccination is crucial, particularly for older adults. Further research is warranted to elucidate the underlying mechanisms linking vaccines and GBS.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Jeong</LastName><ForeName>Yi Deun</ForeName><Initials>YD</Initials><AffiliationInfo><Affiliation>Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Seoyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea. psy091222222@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lee</LastName><ForeName>Sooji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Woojin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jaeyu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kyeongmin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jinseok</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Kyung Hee University, Yongin, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Jiseung</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Udeh</LastName><ForeName>Raphael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahmati</LastName><ForeName>Masoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Health Service Research and Quality of Life Center (CEReSS), Aix-Marseille Université, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physical Education and Sport Sciences, Faculty of Literature and Human Sciences, Lorestan University, Khoramabad, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physical Education and Sport Sciences, Faculty of Literature and Humanities, Vali-E-Asr University of Rafsanjan, Rafsanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeo</LastName><ForeName>Seung Geun</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head &amp; Neck Surgery, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for Health, Performance and Wellbeing, Anglia Ruskin University, East Rd, Cambridge, CB1 1PT, UK. Lee.Smith@aru.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hayeon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Kyung Hee University, Yongin, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yon</LastName><ForeName>Dong Keon</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea. yonkkang@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea. yonkkang@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Regulatory Science, Kyung Hee University, Seoul, South Korea. yonkkang@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea. yonkkang@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RS-2023-00248157</GrantID><Agency>National Research Foundation of Korea</Agency><Country /></Grant><Grant><GrantID>IITP-2024-RS-2024-00438239</GrantID><Agency>Ministry of Science and ICT, South Korea</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020275" MajorTopicYN="Y">Guillain-Barre Syndrome</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Global</Keyword><Keyword MajorTopicYN="N">Guillain-Barré syndrome</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword><Keyword MajorTopicYN="N">Vaccine-associated Guillain-Barré syndrome</Keyword><Keyword MajorTopicYN="N">World Health Organization</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>23</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39427003</ArticleId><ArticleId IdType="pmc">PMC11490553</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-74729-2</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-74729-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Watson, O. J. et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect. Dis. 22, 1293–1302. 10.1016/s1473-3099(22)00320-6 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9225255</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, S. et al. Short- and long-term neuropsychiatric outcomes in long COVID in South Korea and Japan. Nat. Hum. Behav. 8, 1530–1544. 10.1038/s41562-024-01895-8 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38918517</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty, C., Bhattacharya, M. &amp; Dhama, K. SARS-CoV-2 vaccines, vaccine development technologies, and significant efforts in vaccine development during the pandemic: the lessons learned might help to fight against the next pandemic. Vaccines (Basel). 11 10.3390/vaccines11030682 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10054865</ArticleId><ArticleId IdType="pubmed">36992266</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo, H. G. et al. Global burden of vaccine-associated multiple sclerosis, 1967–2022: a comprehensive analysis of the international pharmacovigilance database. J. Med. Virol. 96, e29591. 10.1002/jmv.29591 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38572940</ArticleId></ArticleIdList></Reference><Reference><Citation>Patone, M. et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat. Med. 27, 2144–2153. 10.1038/s41591-021-01556-7 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8629105</ArticleId><ArticleId IdType="pubmed">34697502</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, M. S. et al. Long-term autoimmune inflammatory rheumatic outcomes of COVID-19: a binational cohort study. Ann. Intern. Med. 177, 291–302. 10.7326/m23-1831 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38437702</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, J. et al. National prevalence and determinants of COVID-19 vaccine hesitancy during the initial phase pandemic. Eur. Rev. Med. Pharmacol. Sci. 27, 8280–8290. 10.26355/eurrev_202309_33588 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37750655</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, H. J., Park, H., Yon, D. K. &amp; Rahmati, M. National trends in influenza vaccination coverage rates in South Korea between 2007–2020, including the COVID-19 pandemic: a longitudinal nationwide serial study. Life Cycle 3, e9. 10.54724/lc.2023.e9 (2023).</Citation></Reference><Reference><Citation>Shahrizaila, N., Lehmann, H. C. &amp; Kuwabara, S. Guillain-Barré syndrome. Lancet 397, 1214–1228. 10.1016/s0140-6736(21)00517-1 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33647239</ArticleId></ArticleIdList></Reference><Reference><Citation>Principi, N. &amp; Esposito, S. Vaccine-preventable diseases, vaccines and Guillain-Barre’ syndrome. Vaccine 37, 5544–5550. 10.1016/j.vaccine.2018.05.119 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">29880241</ArticleId></ArticleIdList></Reference><Reference><Citation>Goud, R. et al. Risk of Guillain-Barré Syndrome following recombinant zoster vaccine in medicare beneficiaries. JAMA Intern. Med. 181, 1623–1630. 10.1001/jamainternmed.2021.6227 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8561433</ArticleId><ArticleId IdType="pubmed">34724025</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindquist, M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inform. J. 42, 409–419. 10.1177/009286150804200501 (2008).</Citation></Reference><Reference><Citation>Min, C. The importance of a World Health Organization international pharmacovigilance database (VigiBase): novel methods for safety monitoring and surveillance of medical products. Life Cycle 2, e13. 10.54724/lc.2022.e13 (2022).</Citation></Reference><Reference><Citation>Jeong, Y. D. et al. Global and regional burden of vaccine-associated facial paralysis, 1967–2023: findings from the WHO international pharmacovigilance database. J. Med. Virol. 96, e29682. 10.1002/jmv.29682 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38783823</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong, Y. D. et al. Global burden of vaccine-associated angioedema and their related vaccines, 1967–2023: findings from the global pharmacovigilance database. Allergy10.1111/all.16304 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">39212223</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta, S. et al. Analysis of neurological adverse events reported in VigiBase from COVID-19 vaccines. Cureus 14, e21376. 10.7759/cureus.21376 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8852793</ArticleId><ArticleId IdType="pubmed">35198288</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozzicato, P. MedDRA. Pharm. Med. 23, 65–75. 10.1007/BF03256752 (2009).</Citation></Reference><Reference><Citation>Park, S. et al. Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase. Sci. Rep. 11, 14293. 10.1038/s41598-021-93750-3 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8275737</ArticleId><ArticleId IdType="pubmed">34253801</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen, D. D. et al. Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA Dermatol. 157, 35–42. 10.1001/jamadermatol.2020.3385 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7658800</ArticleId><ArticleId IdType="pubmed">33175100</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, S. et al. Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: findings with critical reanalysis from the WHO pharmacovigilance database. J. Med. Virol. 96, e29693. 10.1002/jmv.29693 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38859751</ArticleId></ArticleIdList></Reference><Reference><Citation>Trillenberg, P., Sprenger, A. &amp; Machner, B. Sensitivity and specificity in signal detection with the reporting odds ratio and the information component. Pharmacoepidemiol. Drug Saf. 32, 910–917. 10.1002/pds.5624 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36966482</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, S. et al. Global burden of vaccine-associated hepatobiliary and gastrointestinal adverse drug reactions, 1967–2023: a comprehensive analysis of the international pharmacovigilance database. J. Med. Virol. 96, e29792. 10.1002/jmv.29792 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38993028</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, K. et al. Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: a multi-nationwide cohort study from South Korea, Japan, and the UK. Clin. Mol. Hepatol.10.3350/cmh.2024.0203 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">39205608</ArticleId></ArticleIdList></Reference><Reference><Citation>Park, G., Jung, H., Heo, S. J. &amp; Jung, I. Comparison of data mining methods for the signal detection of adverse drug events with a hierarchical structure in postmarketing surveillance. Life (Basel) 10 10.3390/life10080138 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7460123</ArticleId><ArticleId IdType="pubmed">32764444</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen, L. S. et al. Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database. Nat. Commun. 13, 25. 10.1038/s41467-021-27631-8 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8748719</ArticleId><ArticleId IdType="pubmed">35013204</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenioux, C. et al. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Nat. Med. 29, 3100–3110. 10.1038/s41591-023-02591-2 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37884625</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, Y. et al. Acute and post-acute respiratory complications of SARS-CoV-2 infection: population-based cohort study in South Korea and Japan. Nat. Commun. 15, 4499. 10.1038/s41467-024-48825-w (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11130304</ArticleId><ArticleId IdType="pubmed">38802352</ArticleId></ArticleIdList></Reference><Reference><Citation>Martín Arias, L. H., Sanz, R., Sáinz, M., Treceño, C. &amp; Carvajal, A. Guillain-Barré syndrome and influenza vaccines: a meta-analysis. Vaccine 33, 3773–3778. 10.1016/j.vaccine.2015.05.013 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25999283</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, M., Nie, S., Qiao, Y. &amp; Ma, Y. Guillain-Barre syndrome following COVID-19 vaccines: a review of literature. Front. Immunol. 14, 1078197. 10.3389/fimmu.2023.1078197 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9975597</ArticleId><ArticleId IdType="pubmed">36875094</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson, K. E. et al. Incidence of Guillain-Barré Syndrome after COVID-19 vaccination in the vaccine safety datalink. JAMA Netw. Open 5, e228879. 10.1001/jamanetworkopen.2022.8879 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9044108</ArticleId><ArticleId IdType="pubmed">35471572</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo, E. J. et al. Association of receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barré syndrome, February–July 2021. Jama 326, 1606–1613. 10.1001/jama.2021.16496 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8498927</ArticleId><ArticleId IdType="pubmed">34617967</ArticleId></ArticleIdList></Reference><Reference><Citation>Willison, A. G. et al. SARS-CoV-2 vaccination and neuroimmunological disease: a review. JAMA Neurol. 81, 179–186. 10.1001/jamaneurol.2023.5208 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38227318</ArticleId></ArticleIdList></Reference><Reference><Citation>Abara, W. E. et al. Reports of Guillain-Barré syndrome after COVID-19 vaccination in the United States. JAMA Netw. Open 6, e2253845. 10.1001/jamanetworkopen.2022.53845 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9892957</ArticleId><ArticleId IdType="pubmed">36723942</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao, S. C. et al. Guillain-​Barré syndrome associated with COVID-19 vaccination. Emerg. Infect. Dis. 27, 3175–3178. 10.3201/eid2712.211634 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8632191</ArticleId><ArticleId IdType="pubmed">34648420</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito, S. &amp; Longo, M. R. Guillain-Barré syndrome. Autoimmun. Rev. 16, 96–101. 10.1016/j.autrev.2016.09.022 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27666816</ArticleId></ArticleIdList></Reference><Reference><Citation>Keh, R. Y. S. et al. COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database. Brain 146, 739–748. 10.1093/brain/awac067 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903477</ArticleId><ArticleId IdType="pubmed">35180300</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishara, H. et al. Association between Guillain-Barré syndrome and COVID-19 infection and vaccination: a population-based nested case-control study. Neurology 101, e2035–e2042. 10.1212/wnl.0000000000207900 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10662985</ArticleId><ArticleId IdType="pubmed">37852786</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs, B. C. et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 51, 1110–1115. 10.1212/wnl.51.4.1110 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9781538</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg, B. et al. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat. Rev. Neurol. 10, 469–482. 10.1038/nrneurol.2014.121 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25023340</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuki, N. &amp; Hartung, H. P. Guillain-Barré syndrome. N. Engl. J. Med. 366, 2294–2304. 10.1056/NEJMra1114525 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22694000</ArticleId></ArticleIdList></Reference><Reference><Citation>Nachamkin, I. et al. Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barré syndrome. J. Infect. Dis. 198, 226–233. 10.1086/589624 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18522505</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourdette, D. &amp; Silbermann, E. What are the risks of Guillain-Barré syndrome after SARS-CoV-2 infection and COVID-19 vaccination?. Neurology 101, 875–876. 10.1212/wnl.0000000000207998 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37852787</ArticleId></ArticleIdList></Reference><Reference><Citation>Fineberg, H. V. Pandemic preparedness and response–lessons from the H1N1 influenza of 2009. N. Engl. J. Med. 370, 1335–1342. 10.1056/NEJMra1208802 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24693893</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, E. R., McNeil, M. M., Moro, P. L., Duffy, J. &amp; Su, J. R. The reporting sensitivity of the vaccine adverse event reporting system (VAERS) for anaphylaxis and for Guillain-Barré syndrome. Vaccine 38, 7458–7463. 10.1016/j.vaccine.2020.09.072 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11252891</ArticleId><ArticleId IdType="pubmed">33039207</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadiq, A., Bostan, N., Yinda, K. C., Naseem, S. &amp; Sattar, S. Rotavirus: genetics, pathogenesis and vaccine advances. Rev. Med. Virol. 28, e2003. 10.1002/rmv.2003 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30156344</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelmoneim, S. A. et al. COVID-19 vaccine booster dose acceptance: systematic review and meta-analysis. Trop. Med. Infect. Dis. 710.3390/tropicalmed7100298 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9611447</ArticleId><ArticleId IdType="pubmed">36288039</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health, O. BCG vaccine: WHO position paper, February 2018—recommendations. Vaccine 36, 3408–3410. 10.1016/j.vaccine.2018.03.009 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29609965</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>